Dipòsit Digital de Documents de la UAB
Publication
Artículo científico (JournalArticle)
Synaptic vulnerability to amyloid-β and tau pathologies differentially disrupts emotional and memory neural circuits
Alzheimer's disease (AD) is characterized by memory loss and neuropsychiatric symptoms associated with cerebral amyloid-β (Aβ) and tau pathologies, but whether and how these factors differentially disrupt neural circuits remains unclear. Here, we investigated the vulnerability of memory and emotional circuits to Aβ and tau pathologies in mice expressing mutant human amyloid precursor protein (APP), Tau or both APP/Tau in excitatory neurons. APP/Tau mice develop age- and sex-dependent Aβ and phosphorylated tau pathologies, the latter exacerbated at early stages, in vulnerable brain regions. Early memory deficits were associated with hippocampal tau pathology in Tau and APP/Tau mice, whereas anxiety and fear appeared linked to intracellular Aβ in the basolateral amygdala (BLA) of APP and APP/Tau mice. Transcriptome hippocampal profiling revealed gene changes affecting myelination and RNA processing in Tau mice, and inflammation and synaptic-related pathways in APP/Tau mice at 6 months. At 9 months, we detected common and region-specific changes in astrocytic, microglia and 63 AD-associated genes in the hippocampus and BLA of APP/Tau mice. Spatial learning deficits were associated with synaptic tau accumulation and synapse disruption in the hippocampus of Tau and APP/Tau mice, whereas emotional disturbances were linked to Aβ pathology but not synaptic tau in the BLA. Interestingly, Aβ and tau exhibited synergistic detrimental effects in long-term potentiation (LTP) in the hippocampus but they counteract with each other to mitigate LTP impairments in the amygdala. These findings indicate that Aβ and tau pathologies cause region-specific effects and synergize to induce synaptic dysfunction and immune responses, contributing to the differing vulnerability of memory and emotional neural circuits in AD.
Project:
Agencia Estatal de Investigación PID2019-106615RB-I00
,
Agencia Estatal de Investigación PID2022-137668OB-I00
,
Agencia Estatal de Investigación PDC2021-121350-I00
,
Agencia Estatal de Investigación PID2019-107677GB-I00
,
Agencia Estatal de Investigación PID2022-136597NB-I00
,
Agencia Estatal de Investigación SAF2017-89271-R
,
Agencia Estatal de Investigación PID2020-11751ORB-I00
,
Agencia Estatal de Investigación PID2023-151925OB-I00
,
Ministerio de Sanidad y Consumo CB06/05/0042
,
Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-00142
,
European Commission 101061171
,
Agencia Estatal de Investigación BES-2017-082072